Xeris Pharmaceuticals share price logo

Xeris Pharmaceuticals

NASDAQ: XERS

Small Cap

$10.64

+0.19

(+1.82%)

as on

Xeris Pharmaceuticals Stock Performance

as on October 29, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $10.43
    $10.75
    downward going graph

    1.97%

    Downside

    1.03%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $5.25
    $11.42
    downward going graph

    50.66%

    Downside

    7.28%

    Upside

    downward going graph

Xeris Pharmaceuticals share price movements today

Previous Close
$10.45
Open
$10.47
Volume
1.1M
Market Cap
$1.9B
Day's Low - High
$10.43 - $10.75
52 Week Low - High
$5.25 - $11.42

Xeris Pharmaceuticals Historical Returns

1 Month Return
+ 6.61 %
3 Month Return
+ 26.97 %
1 Year Return
+ 10.6 %
3 Year Return
+ 560.87 %
5 Year Return
+ 472.04 %

Xeris Pharmaceuticals Stock Fundamentals & Key Indicators

Check Xeris Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.9B

EPS (TTM)

-0.0971

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-107.62

Industry PE ratio

1.41

PEG Ratio

0.01

EBITDA

16.6M

Revenue (TTM)

335.4M

Profit Margin

83.34%

Return On Equity TTM

-426.33%

Xeris Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Xeris Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$1.9B472.04%-107.6283.34%0.00%
Buy$43.5BNA66.4747.54%1.03%
StrongBuy$25.4B207.44%19.5686.14%0.00%
Buy$21.5B40.60%-52.0034.83%2.56%
Buy$44.0BNA20.7365.57%1.96%

Stock Returns calculator for Xeris Pharmaceuticals Stock including INR - Dollar returns

The Xeris Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Xeris Pharmaceuticals investment value today

Current value as on today

₹1,19,360

Returns

₹19,360

(+19.36%)

Returns from Xeris Pharmaceuticals Stock

₹10,603 (+10.6%)

Dollar Impact

₹8,757 (+8.76%)

Analyst Recommendation on Xeris Pharmaceuticals Stock

Based on 2 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 2 analysts, 50% of analysts recommend a 'BUY' rating for Xeris Pharmaceuticals. Average target price of $12.86

Xeris Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Xeris Pharmaceuticals.

What analysts predicted

17.26%UPSIDE

Target Price

$12.86

Current Price

$10.64

Analyzed by

2 Analysts

High

$12

Target

$12.86

Low

$8

Xeris Pharmaceuticals target price $12.86, a slight upside of 17.26% compared to current price of $10.64. According to 2 analysts rating.

Indian Investors' Interest in Xeris Pharmaceuticals Stock

Search interest for Xeris Pharmaceuticals Stock has increased by 44% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:44% versus previous 30 day period

Xeris Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
40
48
54
60
60
71
74
85
83
92
Gross Profit
34
37
40
50
51
56
63
66
69
79
Operating Income
-14
-8
-12
1
-3
4
6
16
7
5
EBITDA
-8
-3
-8
5
1
8
11
14
12
-20
Interest Expense
7
7
7
7
7
7
7
7
6
6
Depreciation
3
3
3
3
3
3
3
3
3
3
Income Before Tax
-18
-14
-19
-5
-9
-1
0
11
2
-31
Income Tax Expense
0
0
-3
-
-
-
-
-
-
-
Net Income
-18
-15
-15
-5
-9
-1
0
11
2
-31
Net Profit Margin
85.31%
78.15%
74.95%
84.23%
85.48%
79.58%
85.22%
77.77%
84.02%
86.41%

Xeris Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
2
2
20
49
110
163
203
291
Gross Profit
1
2
1
11
36
87
135
166
238
Operating Income
-26
-59
-122
-83
-115
-81
-44
-33
24
EBITDA
-26
-57
-117
-79
-113
-69
-23
-13
12
Interest Expense
0
2
7
7
7
14
26
33
29
Depreciation
0
0
1
1
1
12
13
12
12
Income Before Tax
-26
-60
-126
-91
-122
-96
-63
-57
0
Income Tax Expense
0
-
0
0
-
-1
-1
-2
-
Net Income
-26
-60
-125
-91
-122
-94
-62
-54
0
Net Profit Margin
99.74%
98.30%
41.11%
54.35%
73.14%
79.47%
82.52%
81.86%
81.70%

Xeris Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-18
-15
-15
-5
-9
-1
0
11
2
-31
Operating Cash Flow
-20
-10
-8
1
-10
0
18
20
9
8
Investing Cash Flow
-19
4
9
10
0
0
0
0
0
0
Financing Cash Flow
35
0
0
0
-3
0
13
0
-8
1
Change in Cash
-4
-5
1
12
-13
0
32
19
0
9

Xeris Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-26
-60
-91
-91
-122
-94
-62
-54
0
Operating Cash Flow
-24
-56
-80
-80
-95
-102
-47
-36
28
Investing Cash Flow
0
-68
-27
-27
97
34
-6
4
0
Financing Cash Flow
35
128
126
126
27
127
-1
36
11
Change in Cash
9
3
18
18
29
59
-54
4
39

Global Institutional Holdings in Xeris Pharmaceuticals

Check out the Institutions with significant holdings in Xeris Pharmaceuticals.

Funds
Holdings
Vanguard
5.08%
iShares
4.31%
VANGUARD INDEX FUNDS
3.73%
TIAA-CREF Funds
1.33%
SPDR
1.00%

Xeris Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 09 September

    Wed, 06:07 PM

    -

    Xeris Biopharma hosts webinar detailing XP-8121 development strategy and commercial opportunity for hypothyroidism treatment.

Insights on Xeris Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, XERS stock has moved up by 27.0%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, XERS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 83.12M → 92.10M (in $), with an average increase of 9.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 82.8% return, outperforming this stock by 72.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 11.08M → -31.10M (in $), with an average decrease of 786.0% per quarter

About Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
OrganisationXeris Pharmaceuticals
Headquarters1375 West Fulton Street, Chicago, IL, 60607, US
IndustryBiotechnology
CEOJohn Shannon

Key Management of Xeris Pharmaceuticals

Name

Title

Mr. Kevin McCulloch

President & COO

Mr. Steven M. Pieper

Chief Financial Officer

Ms. Beth P. Hecht J.D.

Chief Legal Officer & Corporate Secretary

Dr. Anh T. Nguyen M.B.A., M.D.

Chief Medical Officer

Mr. Brian Conner

SVP of Quality and Chief Compliance & Risk Officer

Ms. Kendal Korte

Senior Vice President of Human Resources

Joshua Bennett

Vice President of Strategy & Business Development

Mr. John P. Shannon

Chairman & CEO

FAQs

What is Xeris Pharmaceuticals share price today?

Xeris Pharmaceuticals share price today is $10.64 as on at the close of the market. Xeris Pharmaceuticals share today touched a day high of $10.75 and a low of $10.43.

What is the 52 week high and 52 week low for Xeris Pharmaceuticals share?

Xeris Pharmaceuticals share touched a 52 week high of $11.42 on and a 52 week low of $5.25 on . Xeris Pharmaceuticals stock price today i.e. is closed at $10.64,which is 6.79% down from its 52 week high and 102.67% up from its 52 week low.

What is Xeris Pharmaceuticals's market capitalisation today?

Xeris Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Xeris Pharmaceuticals Stock (XERS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Xeris Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Xeris Pharmaceuticals Stock (XERS) from India?

Indian investors can start investing in Xeris Pharmaceuticals (XERS) shares with as little as ₹95.22000122070312 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.20 in Xeris Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Xeris Pharmaceuticals share’s latest price of $10.64 as on October 29, 2026 at 8:46 am IST, you will get 0.9398 shares of Xeris Pharmaceuticals. Learn more about fractional shares .

What are the returns that Xeris Pharmaceuticals has given to Indian investors in the last 5 years?

Xeris Pharmaceuticals stock has given 472.04% share price returns and 27.28% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?